Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Decitabine/Tetrahydrouridine Modified Release Capsules in Healthy Adults
NCT05816356Phase 1Completed
- Sponsor
- EpiDestiny
- Start
- Mar 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of decitabine and tetrahydrouridine in sickle cell disease (SCD) (2 arms), sponsored by EpiDestiny. Primary endpoints: Peak decitabine and tetrahydrouridine concentration in plasma and Decitabine and tetrahydrouridine drug level exposure over 24 hr. Started Mar 2023; status: completed.
02
Drugs
decitabinetetrahydrouridine
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT05816356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05816356.